Skip to main content
Tairo S. Lennix

About

I'm Tairo Soren Lennix, an independent research writer focused on peptide pharmacology, longevity science, and the controlled clinical evidence behind both. I sign articles as Tairo S. Lennix and that is the byline you'll see across this site and on peptidehackerlab.com.

What I do

I read primary literature — randomized trials, mechanistic studies, FDA review documents, ClinicalTrials.gov registrations — and I write reference articles and commentary that explain what the evidence does and doesn't show. The goal is not to advocate for any compound. The goal is to make peer-reviewed peptide research legible to people who weren't trained to read it directly.

Long-form reference work — compound mechanisms, evidence reviews, safety profiles, pharmacokinetics — appears on PeptideHackerLab. This site collects shorter signed commentary on individual trials and review articles, plus the methodology I use to evaluate them.

What I'm not

I am not a physician, pharmacist, or clinical researcher. I do not prescribe, recommend doses, or advise where to buy anything. Nothing I write is medical advice. If you are weighing a clinical decision, that conversation belongs with a qualified healthcare professional who knows your history.

I am also not anonymous-by-default. Every article is signed. My research process and the criteria I apply are documented on the methodology page so anyone can audit how a conclusion was reached.

What I cover

  • GHRH analogs — sermorelin (FDA NDA 020272), tesamorelin (NDA 022505), CJC-1295, and the pulsatile growth-hormone literature.
  • GLP-1 receptor agonists — semaglutide, tirzepatide, retatrutide, with attention to the body-composition, hepatic, and cardiovascular endpoints emerging in 2025-2026 trials.
  • Tissue-repair peptides — BPC-157, TB-500, GHK-Cu — and the persistent gap between preclinical animal models and human evidence.
  • Mitochondrial and longevity peptides — MOTS-c, SS-31 (elamipretide), NAD+, Epithalon — and the difference between what the literature claims and what controlled trials have demonstrated.

Standing principles

  • Cite the primary source. PMID, NCT identifier, FDA NDA number, or DOI. "Studies have shown" without a citation does not appear in my work.
  • Distinguish preclinical from clinical. Rodent and in-vitro evidence is interesting; it does not translate one-to-one to humans, and saying so is part of the job.
  • Name the funders. When a sponsor's interest could shape a result, the sponsor gets named in the article.
  • Update on conflict. When new evidence contradicts an earlier piece, the earlier piece gets updated, not quietly removed.

Contact

Substantive corrections, study tips, and editorial inquiries are welcome. I prioritize messages that include a primary source. The fastest route is to point me at the article that you think is wrong and the citation you think corrects it.

Email: hello@tairoslennix.com